Baseline characteristics of patients at initiation of anti-TNF therapy
| Disease characteristics* | Adalimumab (ADL) (n = 317) | Infliximab (INF) (n = 362) | Etanercept (ETN) (n = 519) | p Value† |
|---|---|---|---|---|
| *Values are given as means with 95% confidence intervals (CI) if not otherwise indicated. When not normally distributed variables, medians and interquartile ranges (IQRs) are reported; †one way analysis of variance (ANOVA) of means or medians for continuous variables. χ2 Test for dichotomous variables; ‡for patients with follow up data only, respectively n = 107, n = 295, n = 425. | ||||
| DAS28, Disease Activity Score based on 28 joints; RADAI, Rheumatoid Arthritis Disease Activity Index; HAQ, Health Assessment Questionnaire; DMARD classical disease modifying antirheumatic drug; rheumatoid factor+, proportion of rheumatoid factor positive patients. | ||||
| Anti-TNF dose, median (IQR) | 40 mg/2 wk (40–40) | 3.2 mg/kg×8 wk (3.0–3.75) | 50 mg/wk (50–50) | |
| Female (%) | 74 | 75 | 74 | 0.89 |
| Age (years) | 53.0 (51.4 to 54.7) | 53.1 (51.7 to 54.5) | 54.4 (53.2 to 55.6) | 0.24 |
| Disease duration (years), median (IQR) | 10.1 (5.6–17.5) | 10.2 (5.0–16.5) | 10.3 (5.7–15.9) | 0.97 |
| Rheumatoid factor+ (%) | 82 | 81 | 78 | 0.33 |
| Follow up (mo)‡, median (IQR) | 10.7 (5.8–12.3) | 18.8 (11.5–28.3) | 23.7 (12.6–35.8) | <0.001 |
| Previous failure of anti-TNF agent (%) | 39 | 12 | 7 | <0.001 |
| Disease activity score (DAS28) | 4.19 (4.02 to 4.36) | 4.54 (4.38 to 4.7) | 4.72 (4.59 to 4.85) | <0.001 |
| RADAI | 4.02 (3.6 to 4.5) | 4.59 (4.37 to 4.81) | 4.85 (4.67 to 5.03) | <0.001 |
| Function disability (HAQ) | 1.25 (1.18 to 1.33) | 1.37 (1.29 to 1.44) | 1.37 (1.31 to 1.43) | 0.04 |
| Concomitant DMARD use (%) | 53 | 93 | 64 | |
| Methotrexate (%) | 37 | 70 | 40 | |
| Leflunomide (%) | 10 | 10 | 10 | |
| Sulfasalazine (%) | 4 | 6 | 6 | |
| Other DMARD (%) | 2 | 7 | 8 | |
| Glucocorticoid use (%) | 41 | 56 | 60 | <0.001 |